Can-Fite BioPharma’s CF602 Erectile Dysfunction Treatment Receives Patent Allowance in Brazil
Can-Fite BioPharma Ltd. has received a Notice of Allowance from Brazil's National Institute of Industrial Property for its patent application on CF602, a drug for treating erectile dysfunction, especially in diabetic patients and those unresponsive to current treatments. CF602, an A3 adenosine receptor allosteric modulator, has shown promise in preclinical studies. This patent expands CF602's intellectual property protection beyond major markets.
Can-Fite BioPharma Ltd. announced it has received a Notice of Allowance from the National Institute of Industrial Property of Brazil for its patent application covering the use of its CF602 drug candidate for the treatment of erectile dysfunction (ED), specifically targeting patients living with diabetes and those who do not respond to current ED treatments. CF602 offers a unique mechanism of action as an A3 adenosine receptor allosteric modulator, and preclinical studies have demonstrated its potential to restore erectile function and improve vascular and endothelial health in diabetic models. This development expands the intellectual property protection for CF602 beyond the major markets where patents have already been granted. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579564-en) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
